This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.
Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.
Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.
Company News For Oct 11, 2018
by Zacks Equity Research
Companies in the news are: CPB, FAST, MYGN, PFE and SHLD
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus
by Sweta Jaiswal
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
Myriad (MYGN) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News For Aug 23, 2018
by Zacks Equity Research
Companies In The News are: TGT,LOW,NAVG,HIG,MYGN
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4
by Zacks Equity Research
Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.
Myriad Genetics (MYGN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 15.15% and 2.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Medtronic (MDT) Q1 Earnings Show Overall Progress?
by Zacks Equity Research
In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q4 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Will Myriad (MYGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
by Zacks Equity Research
The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.
Why is Myriad Genetics (MYGN) Up 18.6% Since Its Last Earnings Report?
by Zacks Equity Research
Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Morgan Stanley Calls Labs 'Safe Havens': Stocks to Watch
by Sweta Jaiswal
With Morgan Stanley calling clinical laboratory services market a safe haven, let's find out what's working in favor and against this burgeoning niche market.
Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio
by Zacks Equity Research
Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.
Myriad Genetics' Prolaris Expands on New Coverage Decisions
by Zacks Equity Research
This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q3 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) likely to deliver solid Q3 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Here's Why You Should Invest in Integer Holdings Right Now
by Zacks Equity Research
Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.
Intuitive Surgical (ISRG) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical's (ISRG) da Vinci platform drives growth in Q1, international sales rise.
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) gains ground on solid EHR platform, stiff competition raises concern.
Can MedSurg Business Aid Boston Scientific (BSX) Q1 Earnings?
by Zacks Equity Research
Boston Scientific's (BSX) MedSurg business is likely to deliver an encouraging show in Q1 on the back of a strong endoscopy, driven by biliary, hemostasis, EndoChoice and Symetis buyouts.
Can LaunchPad Aid LabCorp's (LH) Covance Arm in Q1 Earnings?
by Zacks Equity Research
Labcorp's (LH) multi-year LaunchPad project holds enough promise for growth. Good news is that the company already grossed savings worth $20 million from the same in 2017.